So, the treatment with synthesized Pd1,2LNP as a novel active chemotherapeutic with target treatment for the charged tumor cell has preferred mechanisms with its antitumor activity and is characterized by antiproliferative properties toward different tumor cell lines with actions better than trastuzumab, which only targeted the extracellular domain of the HER-2 protein [36,50]. Here, ERBB2 is linked to neoplasm.